ReviewFrontiers in immunology2016
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation-A systematic review and meta-analysis.Bone marrow transplantation · 2023Pooled it
- Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis.Cell transplantationPooled it
- Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.Journal of immunology research · 2017Trial
- Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks.Cells · 2025Review
- Recipient-specific antibodies in HSCT: current knowledge and future perspectives.Frontiers in immunology · 2025Article
- Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders.International journal of molecular sciences · 2024Review
- Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?Stem cell research & therapy · 2024Review
- Article
- "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.Current treatment options in oncology · 2023Review
- HLA diversity in ethnic populations can affect detection of donor-specific antibodies by single antigen beads.Frontiers in immunology · 2023Article
- The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies.Bone marrow transplantation · 2022Review
- Chimerism analysis for clinicians: a review of the literature and worldwide practices.Bone marrow transplantation · 2022Review
- Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.Frontiers in immunology · 2022Review
- Article
- A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.Human immunology · 2021Review
- Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source.Blood advances · 2020Article
- Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol.Bone marrow transplantation · 2019Article
- HLA Matching in Unrelated Stem Cell Transplantation up to Date.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Review
- HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches.Bone marrow transplantation · 2019Review
- [How we do anti-HLA antibodies detection of quality control better].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a curative treatment for a wide variety of hematological diseases. In 30% of the cases, a geno-identical donor is available. Any other situation displays some level of human leukocyte antigen (HLA) incompatibility between donor and recipient. Deleterious effects of anti-HLA immunization have long been recognized in solid organ transplant recipients. More recently, anti-HLA immunization was shown to increase the risk of primary graft failure (PGF), a severe complication of AHSCT that occurs in 3-4% of matched unrelated donor transplantation and up to 15% in cord blood transplantation and T-cell depleted haplo-identical stem cell transplantation. Rates of PGF in patients with DSA were reported to be between 24 and 83% with the highest rates in haplo-identical and cord blood transplantation recipients. This led to the recommendation of anti-HLA antibody screening to detect donor-specific antibodies (DSA) in recipients prior to AHSCT. In this review, we highlight the role of anti-HLA antibodies in AHSCT and the mechanisms that may lead to PGF in patients with DSA, and discuss current issues in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.